Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST: Pyrotinib extended adjuvant therapy
NCT05880927Phase 2Recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jan 2019
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Taizhou Hospital of Zhejiang Province. Started Jan 2019; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05880927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880927.